Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma

The discovery of activating BRAF mutations in approximately 50% of melanomas has led to the development of MAPK pathway inhibitors, which have transformed melanoma therapy. However, not all BRAF-V600E melanomas respond to MAPK inhibition. Therefore, it is important to understand why tumors with the...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Krepler, Clemens, Xiao, Min, Samanta, Minu, Vultur, Adina, Chen, Hsin-Yi, Brafford, Patricia, Reyes-Uribe, Patricia I., Halloran, Molly, Chen, Thomas, He, Xu, Hristova, Denitsa, Liu, Qin, Samatar, Ahmed A., Davies, Michael A., Nathanson, Katherine L., Fukunaga-Kalabis, Mizuho, Herlyn, Meenhard, Villanueva, Jessie
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342073/
https://ncbi.nlm.nih.gov/pubmed/27655717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12078
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items